We use cookies

Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.

You can change your choice at any time.

MMedXYNews
HomeVideos
MedXY AI/MedXY News/Section: Clinical Updates

Neuroretinal Layer Thinning on OCT Imaging and Hemoglobin A1c in Youth With Type 1 Diabetes: Emerging Insights and Clinical Implications

MedXY Editorial Team•Jul 2, 2026•Clinical Updates
diabetic retinal diseasehemoglobin A1cneuroretinal thinningtype 1 diabetes光学干渉断層撮影

Highlights

  • Neuroretinal layer thinning, specifically in the ganglion cell and inner plexiform layers, occurs in youth with type 1 diabetes even before clinical diabetic retinal disease is evident.
  • Higher hemoglobin A1c levels correlate with reduced thickness of key neuroretinal layers, suggesting glycemic control influences early neurodegenerative changes.
  • Optical coherence tomography (OCT) offers a noninvasive biomarker to detect early diabetic retinal neurodegeneration, potentially improving screening and prognostication in pediatric diabetes care.

Background

Type 1 diabetes (T1D) commonly affects youth and carries a significant risk of diabetic retinal disease (DRD), a leading cause of vision loss. Traditionally, DRD diagnosis relies on detection of retinal vascular changes; however, accumulating evidence shows that neural retinal degeneration precedes these vascular manifestations. Understanding early neurodegeneration is critical to improve early diagnosis, risk stratification, and intervention in youth with T1D, a population in which data remain comparatively sparse. Optical coherence tomography (OCT), a high-resolution imaging modality, enables quantitative analysis of discrete retinal layers, offering a unique window into neuroretinal health. This review synthesizes current literature, including new prospective evidence from the ACCESS2 study, correlating retinal layer thinning with glycemic control metrics and early DRD in pediatric T1D cohorts.

Key Content

Chronological Development of Evidence on Neuroretinal Changes in Diabetes

Early studies in adults with T1D demonstrated thinning of inner retinal layers such as the retinal nerve fiber layer (RNFL) and ganglion cell layers prior to overt diabetic retinopathy. Meta-analyses of OCT metrics established these structural changes as consistent biomarkers correlating with disease severity and glycemic indices. However, pediatric data were limited due to challenges in recruiting asymptomatic youth and differences in disease duration and severity.

The recent ACCESS2 prospective cohort (Ramanujam et al., 2026) marked a pivotal advance by enrolling 294 youth aged 9 to 21 years with T1D, characterizing OCT-derived retinal layer thicknesses relative to hemoglobin A1c (HbA1c) and DRD staging. This study uniquely integrated AI-supported segmentation and expert reading center validation, enhancing measurement precision and diagnostic reliability.

OCT-Based Retinal Layer Thickness Findings in Youth With T1D

In this large pediatric cohort (n=578 eyes), the study identified that despite the majority lacking clinical DRD, thinning of neuroretinal layers—particularly the ganglion cell plus inner plexiform layer (GCL+IPL)—correlated inversely with HbA1c levels. Specifically, higher HbA1c was associated with decreased GCL+IPL and outer retinal thickness, suggesting that hyperglycemia contributes to early neurodegeneration independently of measurable vascular damage. Moderate DRD eyes showed trends toward thinner RNFL and GCL+IPL, though these differences did not reach statistical significance possibly reflecting the early disease spectrum.

These findings align with smaller pediatric studies and adult datasets, reinforcing the hypothesis that inner retinal neurodegeneration predates and potentially predicts subsequent vascular retinopathy progression. The data imply that meticulous glycemic control is imperative in mitigating neuroretinal damage early in diabetes course.

Mechanistic Insights Into Diabetic Neuroretinopathy

Experimental models elucidate hyperglycemia-induced retinal neuronal apoptosis, glial dysfunction, and disrupted neurovascular coupling preceding microvascular abnormalities. Oxidative stress, inflammation, and advanced glycation end-products contribute to retinal ganglion cell loss and thinning detectable on OCT. The neurovascular unit concept underscores the intertwined fate of neurons and blood vessels, where early neurodegeneration may serve as a sentinel event signaling retinal vulnerability.

Clinical and Translational Implications

Integrating OCT assessment of neuroretinal layers into routine pediatric diabetes care could enhance early identification of patients at high risk for DRD, enabling personalized monitoring and timely interventions. Furthermore, OCT biomarkers may serve as surrogate endpoints in clinical trials testing neuroprotective or vasculoprotective therapies. Artificial intelligence approaches, as utilized in ACCESS2, promise to streamline retinal image analysis and broaden applicability in clinical practice.

Current screening programs emphasize vascular changes via fundoscopy or fundus photography; the addition of neuroretinal metrics represents a paradigm shift toward a preclinical stage biomarker.

Expert Commentary

While the accumulating evidence supports neuroretinal thinning as an early and clinically relevant manifestation of diabetic retinal disease in youth, challenges remain. The direct causal relationship between elevated HbA1c and retinal thinning needs further clarification through longitudinal studies. The clinical utility of OCT measurements must be balanced against costs, access, and standardization across diverse populations and imaging platforms.

Additionally, variability in OCT segmentation algorithms and normative databases may influence thresholds for pathological thinning. The interpretation of subtle thickness differences requires careful clinical correlation. Nonetheless, findings from the ACCESS2 study extend prior adult data to youths and underscore the importance of glycemic optimization to preserve neural retinal integrity.

Ongoing research should elucidate whether neuroretinal damage predicts subsequent vascular disease progression and the potential reversibility of these changes with improved metabolic control. The possibility of neuroprotective agents and lifestyle interventions offers an exciting horizon.

Conclusion

The prospect of OCT-detected neuroretinal layer thinning as a biomarker of early diabetic retinal neurodegeneration in youth with T1D is underscored by emerging evidence linking higher HbA1c levels with structural retinal changes prior to clinically visible diabetic retinopathy. These advances spotlight the critical need for early detection and glycemic management to prevent vision-threatening complications. Future research must validate these biomarkers longitudinally, standardize imaging protocols, and integrate neuroretinal assessment into comprehensive pediatric diabetes eye care algorithms.

References

  • Ramanujam S et al. Neuroretinal Layer Thinning on OCT Imaging and Hemoglobin A1c in Youth With Type 1 Diabetes. JAMA Ophthalmol. 2026 Jun 25. PMID: 42348200.
  • Shao EY et al. Retinal nerve fiber layer thinning in diabetes without retinopathy: A systematic review and meta-analysis. Diabetes Care. 2020;43(11):2872-2881. PMID: 32953319.
  • van Dijk HW et al. Early neurodegeneration in the retina of patients with type 2 diabetes: The Rotterdam study. Invest Ophthalmol Vis Sci. 2012;53(6):2715-2719. PMID: 22427545.
  • Antonetti DA et al. Diabetic retinopathy: Seeing beyond glucose-induced microvascular disease. Diabetes. 2021;70(4):831-845. PMID: 33766511.
  • Simó R et al. Neurodegeneration in the diabetic eye: New insights and therapeutic perspectives. Trends Endocrinol Metab. 2018;29(7):439-449. PMID: 29656635.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

Related articles

Open language-specific specialty feeds and department pages.

Advancing SGLT Inhibitor Use for Heart and Kidney Protection in Type 1 Diabetes: Opportunities and ChallengesThis article reviews expert perspectives on the efficacy and safety of SGLT inhibitors for cardiovascular and renal disease in type 1 diabetes, outlines translational insights from type 2 diabetes data, and proposes a roadmap for regulatorySep 15, 2026β-Cell Dysfunction Enhances Prediction of Type 1 Diabetes Progression in Individuals with Single Autoantibody PositivityAssessment of β-cell dysfunction using stimulated glucose and C-peptide measures improves risk stratification for type 1 diabetes progression among single autoantibody-positive relatives, enabling personalized monitoring and targeted intervSep 15, 2026New International Consensus: Screening the General Population for Islet Autoantibodies to Detect Early-Stage Type 1 DiabetesAn international expert consensus recommends practical principles and minimum requirements for general‑population screening for islet autoantibodies to detect early-stage type 1 diabetes, reduce DKA, enable early care and access to disease‑Sep 13, 2026
Loading comments...
MedXY briefing

Get the free newsletter

Evidence-led clinical news, trends, and analysis—delivered to your inbox.

Ask MedXY AI

Most popular

Intimate Health
Five Benefits for Women Continuing Sexual Activity After Menopause
Intimate Health
Why Some Women Have a Strong Sex Drive—And Why Men Shouldn't Worry About It
Nursing & care
How often should a couple have sex?
Intimate Health
Classic Intimacy Recommendations: How to Help Women Reach Orgasm and Enjoy Mutual Pleasure
Intimate Health
What Makes a Woman "Physiologically Addicted" Is Never Money, But These Two Relationship Qualities
© 2026 MedXY
Contact usAbout usPrivacy PolicyMedXY story
Teplizumab Preserves Beta Cell Function in Youth with Newly Diagnosed Type 1 Diabetes: Insights from the PROTECT Trial Per-Protocol Analysis
The PROTECT trial’s per-protocol analysis confirms teplizumab’s efficacy in preserving beta cell function, reducing insulin needs, and improving glycemic control in children and adolescents newly diagnosed with stage 3 type 1 di
Sep 13, 2026
Continuous Glucose Monitoring Using the FreeStyle Libre Pro iQ in Presymptomatic Type 1 Diabetes: Advancements in Early Detection and Risk StratificationThis review examines the role of FreeStyle Libre Pro iQ CGM in differentiating presymptomatic stages of type 1 diabetes and predicting progression to clinical disease, comparing its performance with Dexcom G6 and discussing implications forSep 12, 2026
Rising Incidence of Islet Autoimmunity Among Colorado Children With Moderate-Risk HLA Genotypes: Insights From Longitudinal CohortsA study reveals a significant secular increase in islet autoimmunity incidence among Colorado children from 1993 to 2010, particularly in those with moderate-risk HLA genotypes, highlighting evolving risk profiles beyond known environmentalSep 11, 2026